Overview of the transaction
On March 23, 2026, AQR Capital Management reported the sale of 335,390 shares of IB Acquisition Corp. common stock at a price of $10.80 per share, yielding a total transaction value of $3,618,000. The reported sale price is close to the stock's 52-week high of $11.45. InvestingPro's Fair Value analysis, cited alongside the trade data, indicates the stock is currently overvalued according to that assessment. IB Acquisition Corp. carries a market capitalization of $63.14 million.
Which AQR entities executed the sales
The dispositions were executed across a number of funds and accounts managed by AQR Capital Management. The entities named in the filing include:
- AQR Global Alternative Investment Offshore Fund, L.P.
- AQR Diversified Arbitrage Fund
- AQR Absolute Return Master Account, L.P.
- AQR Apex MS Master Account, L.P.
- AQR TA Global Alpha Fund, L.P.
- AQR Corporate Arbitrage Master Account, L.P.
- AQR TA Legacy Fund, LLC
- AQR UCITS Funds - AQR Apex UCITS Fund
- AQR UCITS Funds - AQR Corporate Arbitrage UCITS Fund
- AQR Arbitrage MA Offshore Fund, L.P.
Post-transaction ownership
Following these sales, AQR Capital Management Holdings, LLC continues to indirectly hold shares in IB Acquisition Corp. through various managed funds. The filing indicates that the manager retains exposure to the position via its suite of accounts.
Market context included in the filing
Supporting data cited in the report notes two additional considerations from InvestingPro: first, the platform offers five further ProTips for IBAC; second, the stock typically exhibits low price volatility in trading. The report also flagged a liquidity metric of concern, reporting a current ratio of 0.31 for the company. The juxtaposition of low volatility and liquidity constraints is presented as context that may help explain continued institutional interest despite balance sheet ratios.
Corporate developments at IB Acquisition
Separately, IB Acquisition Corp. has disclosed a definitive business combination agreement to acquire GNQ Insilico Inc. for $500 million. The transaction reportedly has the backing of a majority of GNQ's shareholders and is expected to close in the third quarter of 2026. In connection with the deal, the companies announced a partnership between GNQ Insilico and a Fortune 100 global technology company to advance AI-driven drug discovery and precision medicine efforts. That collaboration will focus on integrating GNQ's AI platforms with the partner's consulting, cloud, and quantum computing capabilities.
Other related SPAC and audit updates
The report also covers additional deal and governance items in the acquisition and SPAC space. Invest Acquisition Corp appointed CBIZ CPAs as its auditor effective January 14, 2026, following CBIZ's acquisition of Marcum LLP's attest business. CBIZ CPAs will provide audit services for the fiscal year ending December 31, 2024. Separately, Iris Acquisition Corp II completed an initial public offering that raised $168.5 million by selling 16,850,000 units at $10.00 per unit. The offering included an over-allotment option exercised by the underwriter. Each unit consists of one Class A ordinary share and one-half of a redeemable warrant, with a whole warrant providing the right to purchase an additional share at a specified price.
What this means for market participants
The filing documents a sizable institutional sale executed near recent highs while also highlighting deal activity and strategic partnerships within IB Acquisition's reported pipeline. The combination of AQR-managed selling, InvestingPro's valuation signal, and the company's active deal agenda are presented in the filing as the factual elements available to investors and market observers.
Note: This article reports on the transaction and related disclosures as presented in the filing and company announcements.